{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Neutropenic fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Clostridium difficile colitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neutropenic colitis without Clostridium difficile"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Sepsis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Mucositis (grade 1-2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Mucositis (grade 3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Diarrhea (grade 3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hepatic toxicity (grade 3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Peripheral neuropathy (grade 1-2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Toxic death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Graded per the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.\n\nPatients are evaluated from first receiving study treatment until a 30-day follow-up after the conclusion of treatment for adverse events not resulting in death. Adverse events resulting in death will be evaluated through Day +100.\n\nThis outcomes measures the common toxicities observed. Please refer to the Serious Adverse Event and Other Adverse Event sections of the results for further details.","groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"OG000","title":"V-BEAM + Stem Cell Infusion"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 days after end of treatment / Day +100","title":"Toxicity of V-BEAM","type":"SECONDARY","unitOfMeasure":"participants"}